Docetaxel in castration-resistant prostate cancer: A single-centre experience - Abstract

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters.

From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

Written by:
Beatrice D, Davide F, Calogero S, Lucia DB, Mohammed B, Icro M, Vanessa DC, Eleonora MP, Ilaria F, Anna M, Gabriele S, Lorenzo L.   Are you the author?
Department of Radiation-Oncology, University of Florence, Florence, Italy, 1.

Reference: Cancer Invest. 2014 Oct;32(9):445-50.
doi: 10.3109/07357907.2014.958233

PubMed Abstract
PMID: 25259606 Prostate Cancer Section